Sacubitril/valsartan · Entresto

Small molecule

Also known as AHU377, LCZ696

Approvedregulatory verdict

Evidence outlook

Approved: Heart Failure

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Hypertension · Phase 3 · investigational in the US

Also approved (5)
CN
  • Essential hypertension (new indication)
  • Heart failure with reduced ejection fraction
Product first approved 2017novartis.com
JP
  • Chronic heart failure (no subtype restriction; includes HFpEF)
Product first approved 2020pj.jiho.jp
EU
  • Symptomatic chronic heart failure with reduced ejection fraction (adults); later children from 1 year with LV systolic dysfunction
Product first approved 2015EMA
CA
  • ENTRESTO® (sacubitril/valsartan) is indicated for: • the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalisation (see 4 Dosage and Administration ). ENTRESTO should be administered in combination with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) (see 2 Contraindications, 4 Dosage and Administration, 7 Warnings and Precautions and 14 Clinical Trials). ENTRESTO should be...
Product first approved 2015Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (34)
Heart Failure
NCT05508035 · John Paul II Hospital, Krakow
2023-07-13 – 2028-12 · Heart Failure With Moderately Reduced Ejection Fraction
What this study did
NCT06712030 · Puerta de Hierro University Hospital
2025-01 – 2027-06 · Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
What this study did
NCT04128891 · Flinders University
2020-02-01 – 2024-02-01 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT03785405 · Novartis Pharmaceuticals
2019-05-02 – 2023-12-29 · Heart Failure
What this study did
NCT03988634 · Novartis Pharmaceuticals
2019-06-29 – 2022-12-14 · Heart Failure With Preserved Ejection Fraction (HFpEF)
What this study did
NCT02884206 · Novartis Pharmaceuticals
2016-11-23 – 2022-05-16 · Chronic Heart Failure (CHF)
What this study did
NCT03917459 · Novartis Pharmaceuticals
2019-04-16 – 2021-05-25 · Heart Failure, Heart Failure, Systolic, Erectile Dysfunction
What this study did
NCT02924727 · Novartis Pharmaceuticals
2016-12-09 – 2021-02-26 · Acute Myocardial Infarction
What this study did
NCT02468232 · Novartis Pharmaceuticals
2015-06-15 – 2021-02-18 · Heart Failure With Reduced Ejection Fraction (HF-rEF)
What this study did
NCT03552575 · NHS Greater Glasgow and Clyde
2018-07-01 – 2020-07-25 · Heart Failure
What this study did
NCT03909295 · Novartis Pharmaceuticals
2019-05-07 – 2019-11-19 · Heart Failure With Preserved Ejection Fraction (HFpEF)
What this study did
NCT03066804 · Novartis Pharmaceuticals
2017-08-22 – 2019-10-28 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT02900378 · Novartis Pharmaceuticals
2016-12-20 – 2018-04-11 · Chronic Heart Failure With Reduced Ejection Fraction
What this study did
Hypertension
NCT06643819 · Chong Kun Dang Pharmaceutical
2024-10-14 – 2026-12-31 · Essential Hypertension
What this study did
NCT03508739 · University of Pennsylvania
2018-06-01 – 2026-06-30 · Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
What this study did
NCT06236061 · Novartis Pharmaceuticals
2024-04-08 – 2025-12-23 · Hypertension
What this study did
NCT05545059 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-09-24 – 2023-03-31 · Resistant Hypertension
What this study did
NCT01865188 · Novartis Pharmaceuticals
2014-04 – 2015-04 · Hypertension
What this study did
NCT01876368 · Novartis Pharmaceuticals
2013-09 – 2014-08 · Hypertension
What this study did
NCT01785472 · Novartis Pharmaceuticals
2013-04 – 2014-08 · Essential Hypertension
What this study did
NCT01615198 · Novartis Pharmaceuticals
2012-08 – 2013-07 · Essential Hypertension
What this study did
NCT01663233 · Novartis Pharmaceuticals
2012-08 – 2013-05 · Essential Hypertension
What this study did
NCT01646671 · Novartis Pharmaceuticals
2012-07 – 2013-02 · Severe Hypertension
What this study did
Other / comorbidity
NCT06693674 · Mayo Clinic
2025-02-03 – 2028-08 · Congenital Heart Disease
What this study did
NCT04912167 · West China Hospital
2021-11 – 2026-06 · STEMI
What this study did
NCT04853758 · University of Sao Paulo General Hospital
2021-05-06 – 2024-12-01 · Chagas Cardiomyopathy
What this study did
NCT04637555 · Novartis Pharmaceuticals
2021-05-26 – 2023-06-01 · Post Myocardial Infarction
What this study did
NCT04753112 · Germans Trias i Pujol Hospital
2020-10-29 – 2021-09-20 · Pulmonary Hypertension
What this study did
Phase 2/3 (4)
Heart Failure
NCT07023016 · National Heart Institute, Egypt
2023-11-01 – 2025-02-28 · Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD)
What this study did
Hypertension
NCT04971720 · University of Alabama at Birmingham
2022-02-18 – 2027-01-01 · Obesity, Cardiovascular Diseases, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
What this study did
Other / comorbidity
NCT05366101 · Newcastle-upon-Tyne Hospitals NHS Trust
2019-04-01 – 2022-03-31 · Hypertrophic Cardiomyopathy
What this study did
Phase 2 (32)
Heart Failure
NCT04153136 · Massachusetts General Hospital
2020-09-11 – 2025-07-09 · HIV/AIDS, Heart Failure With Preserved Ejection Fraction
What this study did
NCT03760588 · Torbjorn Omland
2019-01-31 – 2024-09-05 · Breast Cancer Female, Heart Failure
What this study did
NCT03928158 · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
2019-05-31 – 2023-12-31 · Heart Failure, Essential Hypertension
What this study did
NCT03005184 · Vanderbilt University Medical Center
2017-09 – 2020-01 · Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
What this study did
NCT03415906 · Hannover Medical School
2017-12-14 – 2018-09-06 · Heart Failure
What this study did
NCT01922089 · Novartis Pharmaceuticals
2013-11 – 2014-08 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT01353508 · Novartis Pharmaceuticals
2011-03 – 2012-08 · Hypertension
What this study did
NCT00887588 · Novartis Pharmaceuticals
2009-11 – 2011-12 · Chronic Heart Failure
What this study did
NCT00913653 · Novartis Pharmaceuticals
2009-05 – 2009-07 · Heart Failure
What this study did
Hypertension
NCT07261098 · Shanghai Chest Hospital
2026-01-01 – 2028-12-31 · Advanced Lung Cancer
What this study did
NCT04637152 · Hospital Geral Roberto Santos
2020-11-11 – 2022-08-17 · Resistant Hypertension, Blood Pressure
What this study did
NCT04687111 · Mark Ledwidge
2015-12-16 – 2021-06-11 · Atrial Remodeling, Myocardial Dysfunction, Left Ventricular Remodeling, Left Ventricular Diastolic Dysfunction, Hypertension, Cardiovascular Morbidity, Fibrosis Myocardial, Inflammatory Myopathy, Atrial Arrhythmia
What this study did
NCT01870739 · Novartis Pharmaceuticals
2013-10 – 2015-06 · Hypertension
What this study did
NCT01692301 · Novartis Pharmaceuticals
2012-12 – 2015-04 · Hypertension
What this study did
NCT01681576 · Novartis Pharmaceuticals
2012-08 – 2013-10 · Salt-sensitive Hypertension
What this study did
NCT01631864 · Novartis Pharmaceuticals
2012-10 – 2013-07 · Hypertension, Concurrent Obesity
What this study did
NCT01601470 · Novartis Pharmaceuticals
2012-09 – 2013-01 · Mild to Moderate Hypertension
What this study did
NCT01256411 · Novartis Pharmaceuticals
2010-11 – 2012-04 · Essential Hypertension
What this study did
NCT01281306 · Novartis Pharmaceuticals
2011-01 – 2011-12 · Systolic Hypertension
What this study did
NCT01193101 · Novartis Pharmaceuticals
2010-08 – 2011-04 · Hypertension
What this study did
NCT00549770 · Novartis Pharmaceuticals
2007-09 – 2008-07 · Hypertension
What this study did
Other / comorbidity
NCT06655480 · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
2025-03-18 – 2027-12-31 · HFpEF, LVDD, Myocardial Fibrosis
What this study did
NCT04055428 · University of Alabama at Birmingham
2020-08-15 – 2027-05-31 · Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism, Energy Expenditure
What this study did
NCT05498181 · Brigham and Women's Hospital
2022-10-11 – 2026-01-31 · Hemodialysis
What this study did
NCT05212597 · Samsung Medical Center
2022-01-12 – 2024-12 · Aortic Valve Insufficiency
What this study did
NCT03553810 · National Heart Centre Singapore
2019-04-12 – 2024-06-28 · Hypertensive Heart Disease
What this study did
NCT04164732 · Novartis Pharmaceuticals
2020-01-08 – 2023-08-22 · Cardiomyopathy, Hypertrophic
What this study did
NCT04149990 · Jacob Moller
2018-10-12 – 2023-06-06 · Myocardial Infarction, Diastolic Dysfunction
What this study did
NCT03832660 · Newcastle University
2019-05-03 – 2022-06-30 · Hypertrophic Cardiomyopathy
What this study did
NCT02636283 · University of Minnesota
2017-12-31 – 2018-11-01 · Peripheral Arterial Disease
What this study did
NCT01621633 · Novartis Pharmaceuticals
2012-09 – 2013-01 · Hepatic Impairment
What this study did
NCT01569828 · Novartis Pharmaceuticals
2009-03 – 2009-09 · Pharmacokinetics, Renal Impaired, Healthy Volunteer
What this study did
Phase 1/2 (4)
Heart Failure
NCT05194111 · Virginia Commonwealth University
2022-08-11 – 2028-11-30 · Heart Failure, Heart Dysfunction
What this study did
NCT05279742 · Horng Chen
2022-11-04 – 2027-04 · Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
What this study did
Other / comorbidity
NCT03872778 · Advanced Accelerator Applications
2019-07-24 – 2025-11-27 · Neoplasms
What this study did
NCT04883528 · Duke University
2021-08-06 – 2023-06-13 · Covid19
What this study did
Phase 1 (9)
Heart Failure
NCT07856043 · Stony Brook University
2027-01-01 – 2028-12-31 · Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
What this study did
NCT07444398 · Khawaja Danish Ali
2026-01-01 – 2026-03-31 · Decompensated Heart Failure
What this study did
NCT06922253 · Humanis Saglık Anonim Sirketi
2024-12-28 – 2025-03-17 · Chronic Heart Failure
What this study did
NCT03771729 · The Second Affiliated Hospital of Harbin Medical University
2018-12-30 – 2019-06-15 · CKD
What this study did
Other / comorbidity
NCT06193187 · Dr. Reddy's Laboratories (Thailand) Limited
2024-01 – 2024-08 · Healthy Volunteers
What this study did
NCT06248112 · Bio-innova Co., Ltd
2024-05-06 – 2024-07-06 · Healthy Subjects
What this study did
NCT03647657 · University Hospital, Basel, Switzerland
2018-12-13 – 2021-12-14 · Thyroid Cancer, Medullary
What this study did
NCT01569815 · Novartis Pharmaceuticals
2009-02 – 2014-08 · Mild and Moderate Renal Impairment
What this study did
Phase 4 (53)
Heart Failure
NCT07631156 · Kyungsub Song
2026-08-12 – 2029-12-30 · Heart Failure With Reduced Ejection Fraction, Heart Failure, Ventricular Dysfunction, Left
What this study did
NCT05465031 · Silesian Centre for Heart Diseases
2024-04-17 – 2029-02 · Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents, Sacubitril/Valsartan, Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Molecular Mechanisms of Pharmacological Action, Heart Failure, Cardiac Toxicity, Cancer, Therapy-Related, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity
What this study did
NCT07572032 · Kyungsub Song
2026-05-20 – 2028-12-20 · Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy, Heart Failure
What this study did
NCT06704633 · Martin Rohacek
2026-06-30 – 2028-11-30 · Heart Failure
What this study did
NCT06218199 · Heart Center Research, LLC
2021-07-08 – 2026-12-31 · Heart Failure, Congestive
What this study did
NCT06536309 · Brigham and Women's Hospital
2026-08-27 – 2026-08-27 · Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis
What this study did
NCT07417215 · University Clinical Hospital Mostar
2026-01-30 – 2026-05-10 · Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis, Sacubitril/Valsartan
What this study did
NCT05991284 · Ziekenhuis Oost-Limburg
2024-02-29 – 2026-05-09 · Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation
What this study did
NCT06035978 · University Hospital Ostrava
2024-03 – 2026-04 · Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction
What this study did
NCT05487261 · Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań
2022-12-13 – 2025-11 · Heart Failure
What this study did
NCT05989503 · Universidade do Porto
2023-08-04 – 2025-07-31 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT04023227 · Novartis Pharmaceuticals
2019-12-10 – 2025-03-31 · Chagas Disease, Heart Failure
What this study did
NCT05164653 · Saga University
2021-12-27 – 2025-03 · Heart Failure
What this study did
NCT04103554 · University of Zagreb
2021-02-05 – 2025-02 · Heart Failure
What this study did
NCT05881720 · Damanhour University
2022-01-01 – 2023-06-19 · Heart Failure
What this study did
NCT04491136 · Novartis Pharmaceuticals
2020-11-11 – 2023-06-08 · Heart Failure
What this study did
NCT04572724 · Shenzhen Second People's Hospital
2020-07-06 – 2023-06 · Peritoneal Dialysis Complication, Hemodialysis Complication, Heart Failure
What this study did
NCT05243199 · Ruijin Hospital
2020-08-01 – 2023-03-08 · CKD5 Stage Dialysis, Heart Failure
What this study did
NCT04191681 · The Cleveland Clinic
2019-11-08 – 2022-12 · Stage D Heart Failure
What this study did
NCT03553303 · Oslo University Hospital
2018-10-16 – 2022-05 · Heart Failure, Systolic
What this study did
NCT05387967 · National Institute of Cardiovascular Diseases, Pakistan
2021-01-01 – 2021-09-30 · Heart Failure, Systolic
What this study did
NCT04688294 · Amir Safwat
2020-01-01 – 2021-07-01 · Heart Failure
What this study did
NCT03506412 · Mayo Clinic
2018-06-25 – 2021-03-23 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT02816736 · Duke University
2017-03-02 – 2020-09-29 · Heart Failure
What this study did
NCT03190304 · University of Sao Paulo General Hospital
2017-06-14 – 2020-09-23 · Heart Failure, Exercise Tolerance, Vasodilation, Body Composition, Muscle Strength
What this study did
NCT03168568 · University of Zurich
2017-05-04 – 2020-09-05 · Heart Failure
What this study did
NCT02916160 · University Hospital, Montpellier
2016-09-22 – 2020-02-27 · Chronic Heart Failure, Sleep Apnea Syndrome
What this study did
NCT02768298 · Novartis Pharmaceuticals
2016-07-12 – 2019-11-25 · Chronic Heart Failure With Reduced Ejection Fraction
What this study did
NCT03279861 · University of Maryland, Baltimore
2017-11 – 2019-11 · Congestive Heart Failure, Hypertension
What this study did
NCT03119623 · Brigham and Women's Hospital
2017-06-01 – 2019-08 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT03717688 · Nicolai Jacob Wewer Albrechtsen
2018-05-17 – 2019-05-14 · Diabetes, Heart Failure
What this study did
NCT02754518 · University of Chicago
2016-04 – 2019-04 · Heart Failure
What this study did
NCT02874794 · Novartis Pharmaceuticals
2016-08-17 – 2019-01-26 · Heart Failure and Reduced Ejection Fraction
What this study did
NCT02788656 · Brigham and Women's Hospital
2016-09 – 2018-11-09 · Congestive Heart Failure
What this study did
NCT02887183 · Novartis Pharmaceuticals
2016-10-25 – 2018-10-22 · Heart Failure
What this study did
NCT02554890 · Novartis Pharmaceuticals
2016-04-29 – 2018-07-24 · Acute Heart Failure
What this study did
NCT02661217 · Novartis Pharmaceuticals
2016-02-12 – 2018-06-20 · Heart Failure With Reduced Ejection Fraction
What this study did
NCT02970669 · Novartis Pharmaceuticals
2016-12-16 – 2018-03-19 · Heart Failure, Reduced Ejection Fraction
What this study did
NCT02787798 · University Hospital, Toulouse
2016-10 – 2018-01 · Heart Failure
What this study did
NCT02690974 · Novartis Pharmaceuticals
2016-03-08 – 2017-11-29 · Hearth Failure With Reduced Ejection Fraction (HFrEF)
What this study did
Hypertension
NCT07910058 · Ruijin Hospital
2026-10-31 – 2029-06-30 · Atrial Fibrillation (Persistent), Catheter Ablation, Non-hypertension, Angiotensin Receptor/Neprilysin Inhibitor
What this study did
NCT05528419 · Shanghai Jiao Tong University School of Medicine
2023-02-06 – 2026-02-01 · Atrial Fibrillation Recurrent, Hypertension
What this study did
NCT06501651 · Sichuan Academy of Medical Sciences
2024-08-01 – 2025-04-10 · Essential Hypertension, Type 2 Diabetes, Nephropathy
What this study did
NCT03738878 · Vanderbilt University Medical Center
2018-11-15 – 2024-12-01 · Hypertension
What this study did
NCT04929600 · Shanghai Jiao Tong University School of Medicine
2021-11-28 – 2023-12 · Hypertension, Left Ventricular Hypertrophy
What this study did
NCT05060588 · Qingdao Central Hospital
2021-10 – 2023-02 · Myocardial Infarction, Hypertension
What this study did
Other / comorbidity
NCT06917664 · China National Center for Cardiovascular Diseases
2025-06-05 – 2027-06 · Coronary Artery Disease, Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin Inhibitor
What this study did
NCT03938389 · Ohio State University
2020-02-25 – 2026-06 · PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure
What this study did
NCT04197050 · RenJi Hospital
2020-02-20 – 2022-11 · Myocardial Injury, Connective Tissue Diseases
What this study did
NCT04342351 · RenJi Hospital
2020-05-01 – 2021-12-30 · Myocardial Infarction
What this study did
Early phase / not applicable (16)
Heart Failure
NCT06900803 · National Taiwan University Hospital
2025-04-07 – 2027-10-31 · Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, Medication Adherence
What this study did
NCT07341893 · Damanhour University
2025-08-01 – 2026-03-30 · Heart Failure
What this study did
NCT07379788 · Rehab Werida
2025-01-01 – 2026-03-01 · Heart Failure
What this study did
NCT07192341 · Kafrelsheikh University
2025-09-27 – 2026-02-01 · Sacubitril/Valsartan, Prosthetic Heart Valve, Heart Failure, Reduced Ejection Fraction
What this study did
NCT05117736 · Montreal Heart Institute
2022-03-15 – 2023-03-12 · Systemic Right Ventricle, Heart Failure
What this study did
NCT04587947 · St. Josefs-Hospital Wiesbaden GmbH
2020-04-01 – 2022-05-31 · Heart Failure Patients
What this study did
NCT03821701 · First Affiliated Hospital Xi'an Jiaotong University
2018-06-01 – 2022-01-31 · Chronic Heart Failure
What this study did
NCT04458285 · Guangdong Provincial People's Hospital
2020-01-01 – 2020-12-31 · Hemodialysis Complication, Heart Failure
What this study did
NCT04107220 · Unity Health Toronto
2016-06 – 2020-06 · Heart Failure
What this study did
Hypertension
NCT07853625 · University of Health Sciences Lahore
2026-10-01 – 2027-05-31 · Hypertension, Left Ventricular Diastolic Dysfunction, Essential (Primary) Hypertension
What this study did
NCT04800081 · LanZhou University
2020-07-09 – 2021-07-09 · Hypertension
What this study did
Other / comorbidity
NCT07491718 · University of Edinburgh
2025-08-08 – 2028-08-09 · Takotsubo Cardiomyopathy
What this study did
NCT03893435 · The Young Investigator Group of Cardiovascular Research
2018-12-01 – 2022-10-01 · Acute Myocardial Infarction
What this study did
NCT05053893 · The Affiliated Hospital of Qingdao University
2021-09-22 – 2022-09-01 · Cardio-Renal Syndrome
What this study did
NCT03791723 · The Second Affiliated Hospital of Chongqing Medical University
2019-06-01 – 2021-12-30 · Atrial Fibrillation, Cardiac Remodeling, Atrial, Sacubitril/Valsartan
What this study did
NCT04092309 · University of Athens
2019-09-20 – 2021-09-01 · Hematopoietic Stem Cell Transplantation, Cardiotoxicity
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Hypertension
NCT06716970 · Wuhan Createrna Science and Technology Co., Ltd
2024-12-30 – 2027-02-28 · Essential Hypertension
What this study did
Phase 2/3 (1)
Heart Failure
NCT05580510 · Instituto Nacional de Cardiologia Ignacio Chavez
2023-02-06 – 2024-03-29 · Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction
What this study did
Phase 2 (2)
Heart Failure
NCT06142383 · Novartis Pharmaceuticals
2023-12-12 – 2024-11-01 · Heart Failure
What this study did
Hypertension
NCT07700875 · Wuhan Createrna Science and Technology Co., Ltd
2022-12-29 – 2023-09-11 · Essential Hypertension
What this study did
Phase 1 (3)
Heart Failure
NCT06266988 · Viatris Inc.
2024-03 – 2024-08 · Chronic Heart Failure
What this study did
Other / comorbidity
NCT07746908 · Center for Bioequivalence Studies and Clinical Research
2025-02-06 – 2025-07-18 · Healthy Participants
What this study did
NCT06273254 · Viatris Inc.
2024-04 – 2024-09 · Bioequivalence Study
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Heart Failure
NCT04575675 · Cheng-Hsin General Hospital
2020-05-29 – 2020-12-30 · Hypotension, Heart Failure
What this study did

Competitive landscape

This drug's own stage for Heart Failure: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sacubitril / Valsartan (Entresto): this drugApprovedSmall moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants
NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo)
NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction.
NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2Weak signalFeatured results are non-efficacy only in this race
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)Partial signal
NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT).
Ivabradine (Corlanor)
ApprovedUS marketing discontinued
Small moleculeIf (funny) channelReliable signal
NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants
Sotagliflozin (Inpefa)ApprovedSmall moleculeSGLT1/2 (dual)Partial signal
NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years
NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years
Torsemide (Soaanz)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Vericiguat (Verquvo)ApprovedSmall moleculeSoluble guanylate cyclasePartial signal
NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met.
NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet gradedNo reviewed efficacy summary in this indication
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
CardiAMPPhase 3Cell therapyCardiac cell therapyPartial signal
NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed
CoramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ferric Derisomaltose (Monoferric / Monofer)Phase 3Iron Complex (iv)Iron repletionWeak signal
NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks.
HiCM-188 (allogeneic iPSC-Cardiomyocytes)Phase 3Cell therapyCardiac cell therapyPartial signalNo reviewed efficacy summary in this indication
Icodextrin (peritoneal Ultrafiltration) (Extraneal)Phase 3Glucose Polymer Solution (peritoneal Dialysis)Peritoneal ultrafiltrationWeak signal
NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99)
Levosimendan (Simdax)Phase 3Small moleculeCardiac troponin C (calcium sensitizer)Partial signal
NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed
NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015).
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
Omecamtiv MecarbilPhase 3Small moleculeCardiac myosin (activator)Reliable signal
NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1%
NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed
OPC-61815 (Samtasu)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1)
QiShenYiQiPhase 3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin)Phase 3Protein / enzyme therapeuticErbB2/ErbB4 (neuregulin pathway)Partial signalNo reviewed efficacy summary in this indication
Rexlemestrocel-LPhase 3Cell therapyMesenchymal precursor cells (MPCs)Weak signalFeatured results are safety only in this race
Sotatercept (Winrevair)Phase 3Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DanicamtivPhase 2/3Small moleculeCardiac myosin (activator)Weak signal
NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts.
IstaroximePhase 2/3Small moleculeNa-K ATPase / SERCA2aPartial signal
NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II)
AC01Phase 2Small moleculeGhrelin receptorWeak signalNo reviewed efficacy summary in this indication
ADR-002KPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Bucindolol (Gencaro)Phase 2Small moleculeBeta-1/beta-2 adrenergic receptor (genotype-guided)Partial signal
NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed
CDR132LPhase 2RNA / oligonucleotidemicroRNA-132Weak signalFeatured results are safety only in this race
Corteria COR-1167Phase 2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
DeramiocelPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HRS-9057Phase 2Small moleculeVasopressin V1a/V2 receptor (dual)Weak signalNo reviewed efficacy summary in this indication
HU6Phase 2Small moleculeMitochondrial uncouplingPartial signal
NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003)
Jia Shen TabletPhase 2BotanicalMulti-target (ginsenoside)Weak signalNo reviewed efficacy summary in this indication
JK07Phase 2Biologic (subtype unspecified)HER3 × ErbB4Weak signalFeatured results are safety only in this race
JTT-861Phase 2Small moleculePyruvate dehydrogenasePartial signalNo reviewed efficacy summary in this indication
Mavacamten (Camzyos)Phase 2Small moleculeCardiac myosin (inhibitor)Weak signalFeatured results are safety only in this race
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationWeak signal
NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract.
PexerelgonPhase 2Small moleculeRelaxin receptor (RXFP1) / relaxinPartial signalNo reviewed efficacy summary in this indication
PF-07328948Phase 2Small moleculeBranched-chain ketoacid dehydrogenase kinase (BDK)not yet gradedNo reviewed efficacy summary in this indication
R2R01Phase 2PeptideRelaxin receptor (RXFP1) / relaxinWeak signalNo reviewed efficacy summary in this indication
RibupatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Safiglipron (HRS-7535)Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TovinontrinePhase 2Small moleculePDE9Partial signalNo reviewed efficacy summary in this indication
Umiposgene Parvec (AB-1002)Phase 2Gene therapy / editingProtein inhibitor-1 (gene therapy)Weak signal
NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%.
XTR003Phase 2Diagnostic (pet Tracer)Myocardial fatty-acid metabolism (PET imaging)not yet gradedNo reviewed efficacy summary in this indication
AAV1.SERCA2aPhase 1/2Gene therapy / editingSERCA2a (gene therapy)not yet gradedNo reviewed efficacy summary in this indication
HS-001Phase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
HucMSC Intramyocardial TherapyPhase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
PolyCorePhase 1/2SolutionPeritoneal ultrafiltrationnot yet gradedNo reviewed efficacy summary in this indication
Anhui HygeianCells EE001Phase 1Biologic (subtype unspecified)Cardiac cell therapyWeak signalNo reviewed efficacy summary in this indication
HJB647Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Long-Acting ANP Analog (LY3971297)Phase 1PeptideNatriuretic peptide receptor (NPR-A)not yet gradedNo reviewed efficacy summary in this indication
SHR-4658Phase 1Peptide—not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 63 furthest-along competitors are listed; 11 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Entresto (Sacubitril/valsartan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4Coronary Artery Disease, Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin InhibitorRecruiting
Est. primary completion 2026-12 · NCT06917664 · CT.gov ↗
What to watch
Phase 2Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism …Recruiting
Est. primary completion 2026-12-31 · NCT04055428 · CT.gov ↗
What to watch
2027 (7)
January 2027 (1)
Phase 2/3HypertensionRecruiting
Est. primary completion 2027-01-01 · NCT04971720 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Heart FailureEnrolling by invitation
Est. primary completion 2027-04 · NCT05279742 · CT.gov ↗
What to watch
Phase 3Heart FailureNot yet recruiting
Est. primary completion 2027-04 · NCT06712030 · CT.gov ↗
What to watch
Early phase / not applicableHypertensionNot yet recruiting
Est. primary completion 2027-04-30 · NCT07853625 · CT.gov ↗
What to watch
December 2027 (3)
Phase 4Heart FailureRecruiting
Est. primary completion 2027-12 · NCT05465031 · CT.gov ↗
What to watch
Phase 2HypertensionNot yet recruiting
Est. primary completion 2027-12-31 · NCT07261098 · CT.gov ↗
What to watch
Phase 2HFpEF, LVDD, Myocardial FibrosisRecruiting
Est. primary completion 2027-12-31 · NCT06655480 · CT.gov ↗
What to watch
2028 (7)
May 2028 (1)
Phase 4Heart FailureRecruiting
Est. primary completion 2028-05-20 · NCT07572032 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1Heart FailureNot yet recruiting
Est. primary completion 2028-06-30 · NCT07856043 · CT.gov ↗
What to watch
August 2028 (3)
Phase 3Heart FailureRecruiting
Est. primary completion 2028-08 · NCT05508035 · CT.gov ↗
What to watch
Phase 3Congenital Heart DiseaseRecruiting
Est. primary completion 2028-08 · NCT06693674 · CT.gov ↗
What to watch
Early phase / not applicableTakotsubo CardiomyopathyRecruiting
Est. primary completion 2028-08-09 · NCT07491718 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1/2Heart FailureRecruiting
Est. primary completion 2028-11-30 · NCT05194111 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2028-11-30 · NCT06704633 · CT.gov ↗
What to watch
2029 (2)
March 2029 (1)
Phase 4HypertensionNot yet recruiting
Est. primary completion 2029-03-31 · NCT07910058 · CT.gov ↗
What to watch
June 2029 (1)
Phase 4Heart FailureRecruiting
Est. primary completion 2029-06-30 · NCT07631156 · CT.gov ↗
What to watch

See the full readout calendar ↗